A Pricing Rule With Global Reach
The Trump administration's push to implement Most Favored Nation drug pricing — a policy that would peg what US federal health programs pay for certain drugs to the lowest price paid by any comparable developed nation — has sent biopharma legal and finance teams into intensive scenario planning. Lawyers who work with major pharmaceutical companies have confirmed that clients are now actively redesigning their international licensing structures to reduce the surface area exposed to potential MFN adjustments.
Most Favored Nation pricing is conceptually straightforward: if France pays a significantly lower price for a drug than the US, MFN would require the US price to converge toward that lower price. The policy's appeal to American patients and payers is obvious. Its implementation mechanics are deeply complex, because prices paid in other countries are often the result of confidential negotiations and rebate arrangements that make headline prices an imperfect representation of actual net costs.
The Licensing Structure Response
The most sophisticated industry response involves restructuring how drugs are licensed to affiliates and partners in international markets. In many biopharma business models, a parent company licenses intellectual property to regional subsidiaries or partner companies in exchange for royalties or milestone payments. The terms of those licensing agreements affect how revenue is recognized, what prices are disclosed in regulatory filings, and ultimately what the MFN calculation would reference when comparing prices across countries.
By adjusting the structure of international licensing deals — through mechanisms like tiered royalty rates, modified milestone payment schedules, or restructuring how value-sharing is distributed between brand and generic partners — companies can reduce the price transparency that MFN calculations depend on. The goal is not necessarily to avoid fair pricing but to ensure that confidential commercial terms in one market are not inadvertently used to set binding price ceilings in another.
Legal Landscape and Regulatory Risk
The legal advisors quoted by industry publications emphasized that the restructuring strategies being contemplated are not evasion schemes — they operate within existing legal frameworks governing pharmaceutical licensing, intellectual property transfers, and multinational corporate structure. The challenge is that MFN pricing policy is itself still evolving, and the specific implementation rules that would determine how reference prices are calculated have not been fully codified.
This regulatory uncertainty cuts both ways. Companies that restructure now based on their best reading of where MFN rules are headed may find that final regulations are written differently, requiring further adaptation. Those that wait for regulatory certainty before acting may find themselves more constrained when rules are finalized.
Biosimilars and Generic Implications
MFN policy has different implications depending on whether a drug is a branded biologic, a small molecule pharmaceutical, or a biosimilar. For branded biologics — large, complex molecules that dominate the highest-cost segment of pharmaceutical spending — the price gaps between the US and other markets are often the largest, making MFN impact potential most acute. For these drugs, the licensing restructuring strategies are most actively being considered.
Biosimilars, which compete with branded biologics at reduced prices after patent expiration, present a different calculus. If MFN pricing reduces reference brand prices, the launch price point for biosimilars needs to adjust accordingly — a dynamic that could affect the competitive economics of biosimilar development and launch decisions.
Patient and Payer Perspectives
From the perspective of patients and payers who bear drug costs, any reduction in US pharmaceutical prices through MFN implementation would be welcome, and the industry's efforts to minimize that reduction through licensing structure changes will inevitably attract criticism as prioritizing shareholder value over patient access.
The pharmaceutical industry's counterargument — that sustained innovation depends on the revenue premium that US prices provide, and that MFN pricing would reduce capital available for early-stage research — is one that policy economists debate without reaching consensus. What is clear is that the MFN policy debate is shaping real business decisions now, well before any final implementation rules are in place, as companies attempt to position themselves for multiple regulatory scenarios simultaneously.
This article is based on reporting by endpoints.news. Read the original article.
